main content start

MedEnrich | Página principal

Continue Watching

últimos vidéos

últimos vidéos

Brightcove Home Latest Listing

Cáncer de mama

Cáncer de mama

Brightcove Cards Listing

Cáncer de próstata

Brightcove Cards Listing

Mieloma múltiple

Mieloma múltiple

Brightcove Cards Listing

Popular en MedEnrich

Popular in Sin nombre
  • Myelodysplastic Syndromes3m 14s

    Low Risk MDS - Key Practice Points

    Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.
    ipss -m low risk molecular features
  • Cáncer de mama11m 28s

    ESR1 Mutation in Hormone Receptor Positive Advanced Breast Cancer

    ESR1 mutation leads to ligand independent activation of estrogen receptor. ESR1 mutations were first described in 1997 & their role remain underestimated as initial research was focused on primary tumor wherein these mutations were absent.
    aromatase inhibitor resistance hr +ve mbc esr1 mutation fulvestrant
  • Cáncer de mama3m 36s

    Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer

    Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
    tumor-infiltrating lymphocytes (tils) promising biomarker
  • Myelodysplastic Syndromes4m 0s

    Selecting Right Patients for Early Initiation in HMAs in Low Risk MDS

    Selecting the right patients for early initiation of hypomethylating agents (HMAs) in low-risk MDS involves identifying those with progressive cytopenias, poor prognostic mutations, or high-risk features despite low-risk classification.
    hypomethylating agents (hmas) disease progression personalised treatment plans low risk mds
  • Mieloma múltiple13m 11s

    Management of Infections in Multiple Myeloma

    Risk of infections in multiple myeloma has increased with the use of Novel treatments like Proteosome inhibitors, CD38 targeting MABs & BCMA targeted drugs.
    prophylaxis infections vaccination myeloma
  • Mieloma múltiple7m 42s

    MRD Assesment in Multiple Myeloma -Ready for Prime Time

    Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
    minimum residual disease (mrd) mrd negativity multiple myeloma
  • Cáncer de mama8m 46s

    Expert Perspective - How I Treat Metastatic Her2 Positive Breast Cancer

    Anti-HER2 directed therapy remains the cornerstone of care for individuals with HER2-positive metastatic breast cancer (MBC).
    anti-her2 directed therapy her2-positive metastatic breast cancer expert perspective algorithm for management of her2 positive mbc
  • Myelodysplastic Syndromes5m 42s

    Integrating Molecular Prognositic Systems in Management of MDS

    Integrating molecular prognostic systems into MDS clinical practice enhances risk stratification by combining genetic data with traditional scoring systems.
    molecular prognostic systems ipss-m prediction of disease progression
  • Cáncer de mama8m 55s

    Understanding HER-2 Low Breast Cancer Entity & Treatment Strategy

    Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.
    trastuzumab-deruxtecan (t-dxd) her2 low breast cancers
  • Myelodysplastic Syndromes2m 25s

    Factors that influence treatment adherence and outcomes in MDS

    Anticipate & manage adverse events to optimize treatment outcomes: Patients treated with hypomethylating agents are at increased risk of cytopenias & might need support with transfusions.
    adverse events hypomethylating agents mds treatment compliance
  • Seminarios web anteriores

    Seminarios web anteriores

    Webinar Cards Listing

    Artículos

    Artículos

    Medbytes Cards Listing
    Hi, can I help?
    Chat de ayudaX
    Equipo de soporte
    ¡Hola! ¿Cómo puedo ayudarlo/a hoy?
    Por favor seleccione alguna de las siguientes opciones.

    Buscar información

    Problemas con el inicio de sesión o registro

    Compartir un comentario